Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)

HealthHORIZON-JU-RIAID: 101163781
EC Contribution
โ‚ฌ30,387
Consortium Size
56 orgs
Start Year
2024
โ–ถSummary

BackgroundHealth systems face a time of unprecedented change, with spiraling costs, increasing cultural disparity in access to healthcare and research, and an infrastructure that is decades old. Today, telehealth is a realistic alternative making care and research more accessible and personalised with less burden to better support the most vulnerable and under-served in our society. The ability to test and monitor for illnesses using Patient Centric micro-Sampling (PCmS) is at the centre of this reform.Aim and main objectivesThis project is designed to build upon existing pilots and knowledge, then collaborate cross-sectorially to co-create and test the logistics, infrastructure and tools required to make PCmS a core healthcare tool and an acceptable alternative to venous blood-draw across Europe. This project aligns with many IHIโ€™s objectives focusing on cross-sectorial collaboration, emphasizing patient and end-user- centric co-design of outputs, harmonised regulatory and data generation approaches enhancing the potential of digital innovations in healthcare, while aiming to reduce the environmental footprint during the project and in final outputs to ensure that the expected long-term impact is a reachable reality that will deliver significant benefit to the community and address unmet public health needs at scale.To achieve our objectives, we bring together a broad group of required expertise, know-how and end-users (i.e., public and patients) to form a public-private-partnership specifically equipped to tackle this challenge. This collaborative approach where the relevant stakeholders such as healthcare professionals, regulatory agencies and patients are involved and integrated to deliver solutions and innovation across healthcare systems and ensure the best chances for success and long-term positive impact from this project.Key deliverables include:1)An optimized, tested and validated โ€˜Gold Standardโ€™ infrastructure and workflow for PCmS across Europe as a proven and reliable alternative to venipuncture2)Harmonised and clear regulatory and HTA pathways, standards and acceptability, measures and cost-benefit models across Europe3)Documented evidence to draw a citable โ€˜line in the sandโ€™ for future research to support decisions to integrate PCmS into decentralised trials and care pathways4)Stakeholder engagement and patient involvement models and research on preferences and acceptability for PCmS5)Foundation for future: Enable access to the developed PCmS scientific findings, tools and assessment measures for rapid uptake and integration of PCmS approaches into decentralised clinical studies and healthcareExpected impact:-Patient-centric microsampling becomes an accepted alternative to the current standard of care venipuncture and the data gathered can be leveraged in healthcare planning.-Lowered patient burden and lowered barrier to access in situations where blood samples need to be collected, whether as part of diagnosis, care plan, health monitoring etc. -A solution to leverage high amounts of data gathered from increased testing can be explored already in this project so that it can pave the way for future research that can improve health outcomes.

Consortium (56)

๐Ÿ‡ฌ๐Ÿ‡ท ARISTOTELIO PANEPISTIMIO THESSALONIKISGR
coordinator
๐Ÿ‡บ๐Ÿ‡ธ ABBVIE INCUS
partner
๐Ÿ‡ธ๐Ÿ‡ช ASTRAZENECA ABSE
partner
๐Ÿ‡ฉ๐Ÿ‡ช BAYER AKTIENGESELLSCHAFTDE
partner
๐Ÿ‡ฌ๐Ÿ‡ง BAYER PUBLIC LIMITED COMPANYGB
partner
๐Ÿ‡ฎ๐Ÿ‡น Bayer SpAIT
partner
๐Ÿ‡ซ๐Ÿ‡ท BECTON DICKINSON FRANCE SASFR
partner
๐Ÿ‡ธ๐Ÿ‡ช CAPITAINER ABSE
partner
๐Ÿ‡ฌ๐Ÿ‡ท COLLABORATE HEALTHCARE- KAINOTOMES YPIRESIES YGEIAS IKEGR
partner
๐Ÿ‡บ๐Ÿ‡ธ ELI LILLY AND COMPANYUS
partner
๐Ÿ‡ฎ๐Ÿ‡ช Eli Lilly Kinsale LtdIE
partner
๐Ÿ‡ซ๐Ÿ‡ท EURAXI PHARMAFR
partner
๐Ÿ‡ง๐Ÿ‡ช EUROPEAN CENTRE FOR CLINICAL RESEARCH TRAININGBE
partner
๐Ÿ‡จ๐Ÿ‡ญ F. HOFFMANN-LA ROCHE AGCH
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCAES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO INSTITUT UNIVERSITARI PERA LA RECERCA A L'ATENCIO PRIMARIA DE SALUT JORDI GOL I GURINAES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO PRIVADA PER A LA RECERCA I LA DOCENCIA SANT JOAN DE DEUES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUDES
partner
๐Ÿ‡ง๐Ÿ‡ช GLAXOSMITHKLINE BIOLOGICALS SABE
partner
๐Ÿ‡ฌ๐Ÿ‡ง GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITEDGB
partner
๐Ÿ‡ช๐Ÿ‡ธ HOSPITAL SANT JOAN DE DEUES
partner
๐Ÿ‡ช๐Ÿ‡ธ INSTITUT CATALA DE LA SALUTES
partner
๐Ÿ‡ซ๐Ÿ‡ท INSTITUT DE RECHERCHES INTERNATIONALES SERVIERFR
partner
๐Ÿ‡ซ๐Ÿ‡ท INSTITUT DE RECHERCHES SERVIERFR
partner
๐Ÿ‡ซ๐Ÿ‡ท INSTITUT PASTEURFR
partner
๐Ÿ‡ธ๐Ÿ‡ช INTERNATIONAL DOPING TESTS MANAGEMENT AB IDTMSE
partner
๐Ÿ‡ง๐Ÿ‡ช IQVIA SOLUTIONS BELGIUMBE
partner
๐Ÿ‡ง๐Ÿ‡ช JANSSEN PHARMACEUTICA NVBE
partner
๐Ÿ‡ฉ๐Ÿ‡ช JONES LANG LASALLE SEDE
partner
๐Ÿ‡ธ๐Ÿ‡ช KAROLINSKA INSTITUTETSE
partner
๐Ÿ‡ฌ๐Ÿ‡ง LABCORP EARLY DEVELOPMENT LABORATORIES LIMITEDGB
partner
๐Ÿ‡ฉ๐Ÿ‡ช Lilly Deutschland GmbHDE
partner
๐Ÿ‡ฌ๐Ÿ‡ง MEDIPACE LIMITEDGB
partner
๐Ÿ‡ฉ๐Ÿ‡ช MIEBACH CONSULTING GMBHDE
partner
๐Ÿ‡จ๐Ÿ‡ญ NOVARTIS PHARMA AGCH
partner
๐Ÿ‡ฌ๐Ÿ‡ง PATIENT CENTRIC SAMPLING INTEREST GROUP CICGB
partner
๐Ÿ‡บ๐Ÿ‡ธ PFIZER INCUS
partner
๐Ÿ‡ฌ๐Ÿ‡ง PFIZER LIMITEDGB
partner
๐Ÿ‡ฌ๐Ÿ‡ง Pfizer R&D UK LimitedGB
partner
๐Ÿ‡ฎ๐Ÿ‡น PHARMA QUALITY EUROPE SRLIT
partner
๐Ÿ‡บ๐Ÿ‡ธ Q Squared Solutions LLCUS
partner
๐Ÿ‡ธ๐Ÿ‡ช REGION STOCKHOLMSE
partner
๐Ÿ‡บ๐Ÿ‡ธ Rhinostics, Inc.US
partner
๐Ÿ‡จ๐Ÿ‡ญ ROCHE DIAGNOSTICS INTERNATIONAL AGCH
partner
๐Ÿ‡ช๐Ÿ‡ธ SERVICIO ANDALUZ DE SALUDES
partner
๐Ÿ‡ฉ๐Ÿ‡ช SIEMENS HEALTHINEERS AGDE
partner
๐Ÿ‡ณ๐Ÿ‡ฑ Stichting Sanquin BloedvoorzieningNL
partner
๐Ÿ‡ณ๐Ÿ‡ฑ STICHTING VUNL
partner
๐Ÿ‡บ๐Ÿ‡ธ Tasso IncUS
partner
๐Ÿ‡ซ๐Ÿ‡ท Technologie ServierFR
partner
๐Ÿ‡ฌ๐Ÿ‡ท THETABIOMARKERS IKEGR
partner
๐Ÿ‡ฌ๐Ÿ‡ง TRAJAN SCIENTIFIC EUROPE LTDGB
partner
๐Ÿ‡ฌ๐Ÿ‡ง UNIVERSITY OF DUNDEEGB
partner
๐Ÿ‡ฌ๐Ÿ‡ง UNIVERSITY OF NEWCASTLE UPON TYNEGB
partner
๐Ÿ‡จ๐Ÿ‡ฟ UNIVERZITA PALACKEHO V OLOMOUCICZ
partner
๐Ÿ‡บ๐Ÿ‡ธ YourBio Health, Inc.US
partner